Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16656
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChiang, Cherie-
dc.date2017-03-
dc.date.accessioned2017-05-24T02:05:26Z-
dc.date.available2017-05-24T02:05:26Z-
dc.date.issued2017-03-
dc.identifier.citationNephrology 2017; 22(S2): 11-13en_US
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/16656-
dc.description.abstractBone turnover markers assist in fracture risk prediction, management and monitoring of osteoporosis in patients without chronic kidney disease (CKD). The use in CKD-mineral bone disorder (MBD) has been limited as many of these markers and breakdown products are renally excreted, including the most commonly used and well standardized procollagen type I N propeptide and C-terminal cross-linking telopeptide of type I collagen. Of the markers unaffected by renal function, bone specific alkaline phosphatase is associated with mortality and fracture rate in CKD subjects and is now available on several automated analysers. When used in combination with PTH, bone specific alkaline phosphatase as a bone formation marker correlated well with bone biopsy histomorphometry in predicting adynamic bone disease. Tartrate-resistant acid phosphatase 5b is a resorption marker that is under development for automation. Both high and low bone turnover in CKD-MBD patients are associated with increased fracture and mortality risk. Bone biopsy as the gold standard to differentiate between adynamic bone disease and osteitis fibrosa is limited by availability and cost. Appropriate use of bone turnover markers is vital in the decision to commence anti-resorptive agents, and to monitor efficacy in order to avoid over suppression of bone turnover, which may lead to stress fractures. Further efforts are required to develop markers unaffected by renal function with standardized cut-off values and fracture as well as vascular calcification end-points.en_US
dc.subjectBone specific alkaline phosphataseen_US
dc.subjectBone turnover markersen_US
dc.subjectChronic kidney diseaseen_US
dc.subjectFractureen_US
dc.subjectParathyroid hormoneen_US
dc.titleThe use of bone turnover markers in chronic kidney disease-mineral and bone disordersen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleNephrologyen_US
dc.identifier.affiliationUniversity of Melbourne, The Royal Melbourne Hospital, Parkville, Victoria, Australiaen
dc.identifier.affiliationDepartment of Endocrinology, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Pathology, Royal Melbourne Hospital, Parkville, Victoria, Australiaen
dc.identifier.affiliationDepartment of Pathology, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/28429547en_US
dc.identifier.doi10.1111/nep.13014en_US
dc.type.contentTexten_US
dc.type.austinJournal Articleen_US
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.cerifentitytypePublications-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

2
checked on Feb 7, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.